Glycopyrrolate Pharmacology

Quick Answer

Glycopyrrolate (glycopyrronium bromide) is a synthetic quaternary ammonium anticholinergic agent that acts as a competitive muscarinic receptor antagonist at M1, M2, and M3 receptor subtypes. Its quaternary ammonium structure renders it permanently charged and highly polar, preventing passage across the blood-brain barrier and placenta, which distinguishes it pharmacologically from tertiary amine anticholinergics such as atropine. The primary anaesthetic applications include co-administration with neostigmine for neuromuscular blockade reversal (standard dose 0.2 mg per 1 mg neostigmine), antisialagogue premedication (0.2-0.4 mg IV/IM), and treatment of intraoperative bradycardia (0.2-0.4 mg IV). Glycopyrrolate produces less tachycardia than atropine and has a longer duration of antisialagogue effect (up to 7 hours). The onset of vagolytic action (2-3 minutes IV) matches neostigmine better than atropine, providing superior haemodynamic stability during neuromuscular reversal. Unlike atropine, glycopyrrolate does not cause central anticholinergic syndrome. Key pharmacokinetic features include poor oral bioavailability (<5%), renal elimination (80% unchanged), and an elimination half-life of 0.6-1.2 hours. [1-8]

Pharmacology Overview

Drug Classification and History

Glycopyrrolate belongs to the anticholinergic (antimuscarinic) class of drugs, representing a synthetic alternative to naturally occurring belladonna alkaloids. The drug was first synthesised in 1961 by Robins Pharmaceuticals and gained FDA approval in 1961 for gastrointestinal disorders before becoming widely adopted in anaesthetic practice. Chemically classified as a quaternary ammonium compound, glycopyrrolate was developed to provide peripheral anticholinergic effects without the central nervous system actions characteristic of tertiary amine anticholinergics like atropine and scopolamine. This structural modification created a drug ideally suited to anaesthetic applications where antisialagogue and vagolytic effects are desired without sedation, confusion, or delirium. The drug is marketed under various trade names including Robinul, Glycopyrronium, and Cuvposa. [1,2]

Chemical Structure and Physicochemical Properties

Glycopyrrolate (glycopyrronium bromide) has the molecular formula C19H28BrNO3 with a molecular weight of 398.3 Da. The IUPAC name is 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. The molecule consists of a cyclopentylmandelic acid ester linked to a dimethylpyrrolidinium moiety, forming a quaternary ammonium structure with a permanent positive charge at physiological pH. [3,4]

Key Physicochemical Properties:

The permanent positive charge on the quaternary nitrogen is the crucial structural feature distinguishing glycopyrrolate from tertiary amine anticholinergics. This charge prevents passive diffusion across lipid bilayer membranes, including the blood-brain barrier and placental barrier. The drug is stable in aqueous solution, compatible with common IV fluids, and can be mixed in the same syringe with neostigmine for reversal of neuromuscular blockade. [5,6]

Comparison of Anticholinergic Structures

The quaternary ammonium structure confers two major clinical advantages: absence of central anticholinergic effects (delirium, sedation, memory impairment) and lack of placental transfer (preventing fetal tachycardia in obstetric anaesthesia). [7,8]

Mechanism of Action: Muscarinic Receptor Antagonism

Muscarinic Receptor Subtypes and Distribution

Glycopyrrolate exerts its pharmacological effects through competitive antagonism at muscarinic acetylcholine receptors (mAChRs). Five muscarinic receptor subtypes (M1-M5) have been identified, all belonging to the G-protein coupled receptor (GPCR) superfamily. Glycopyrrolate has similar affinity for M1, M2, and M3 receptors, with Ki values in the range of 0.5-5 nM, making it a non-selective muscarinic antagonist at clinically relevant concentrations. [9,10]

Muscarinic Receptor Distribution and Effects of Blockade:

Molecular Mechanism

Muscarinic receptors are metabotropic receptors that couple to G-proteins to initiate intracellular signalling cascades:

M2 Receptor Blockade (Cardiac Effects):

• M2 receptors in the sinoatrial (SA) node mediate vagal slowing of heart rate
• Acetylcholine binding activates Gi proteins, which:
  • Inhibit adenylyl cyclase (reduced cAMP)
  • Open K+ channels (GIRK channels) causing hyperpolarisation
  • Inhibit L-type Ca2+ channels
• Result: Slowed spontaneous depolarisation, reduced heart rate
• Glycopyrrolate blockade prevents these effects, producing tachycardia (vagolysis)

M3 Receptor Blockade (Exocrine Glands):

• M3 receptors on salivary glands, tracheobronchial glands, and gastric mucosa mediate secretion
• Acetylcholine binding activates Gq proteins, which:
  • Activate phospholipase C (PLC)
  • Generate IP3 and DAG second messengers
  • Increase intracellular calcium
• Result: Exocytosis and fluid secretion
• Glycopyrrolate blockade reduces salivary, bronchial, and gastric secretions

M3 Receptor Blockade (Smooth Muscle):

• M3 receptors on bronchial and gastrointestinal smooth muscle mediate contraction
• Glycopyrrolate blockade causes bronchodilation and reduced GI motility [11-13]

Receptor Binding Kinetics

Glycopyrrolate is a competitive, reversible antagonist at muscarinic receptors. The binding equilibrium follows the law of mass action, with the magnitude of effect depending on:

1. Glycopyrrolate concentration at the receptor
2. Acetylcholine concentration competing for binding
3. Receptor affinity (expressed as dissociation constant, Kd)

At therapeutic doses, glycopyrrolate achieves sufficient receptor occupancy to block parasympathetic effects without abolishing all cholinergic transmission. The competitive nature of antagonism means that effects can be overcome by high concentrations of acetylcholine (e.g., during neostigmine administration), necessitating timing coordination during neuromuscular reversal. [14,15]

Pharmacokinetic Principles

Absorption

Glycopyrrolate absorption varies significantly by route of administration due to its quaternary ammonium structure:

Intravenous Administration:

• 100% bioavailability (by definition)
• Onset of vagolytic effect: 1-2 minutes
• Onset of antisialagogue effect: 15-30 minutes
• Peak antisialagogue effect: 30-45 minutes

Intramuscular Administration:

• Bioavailability: ~80-90%
• Onset of vagolytic effect: 3-5 minutes
• Peak effect: 30-40 minutes
• Commonly used for premedication

Oral Administration:

• Bioavailability: Very poor (<5%, range 3-10%)
• Quaternary structure limits passive absorption
• High first-pass metabolism of absorbed drug
• Not used in anaesthetic practice; oral formulations exist for chronic conditions (drooling, COPD)

Subcutaneous Administration:

• Bioavailability comparable to IM
• Slower onset than IM
• Used in palliative care for secretion management [16-18]

Distribution

The low volume of distribution reflects the quaternary ammonium structure's inability to cross lipid membranes and enter intracellular compartments. Glycopyrrolate remains predominantly in the extracellular fluid and plasma compartments. This contrasts with atropine (Vd 2-3 L/kg), which distributes widely including into the CNS.

The quaternary ammonium structure ensures glycopyrrolate cannot cross the blood-brain barrier by passive diffusion. This property eliminates the risk of central anticholinergic syndrome (confusion, agitation, hallucinations, memory impairment, sedation) that can occur with atropine.

Placental Transfer: Glycopyrrolate does not cross the placenta in significant quantities due to its polar, ionised structure. Studies during caesarean section have shown fetal-to-maternal plasma ratios of <0.1, indicating minimal placental transfer. This makes glycopyrrolate the preferred anticholinergic in obstetric anaesthesia, avoiding fetal tachycardia and potential fetal CNS effects associated with atropine. [19-22]

Metabolism

Glycopyrrolate undergoes minimal hepatic metabolism. The quaternary structure limits access to hepatic cytochrome P450 enzymes. What metabolism does occur involves:

• Hydrolysis of the ester bond (minor pathway)
• Mandelic acid metabolite (inactive)
• Pyrrolidine metabolite (inactive)

The low extent of metabolism (<20% of dose) means hepatic impairment has minimal impact on glycopyrrolate clearance, and no dose adjustment is required in liver disease. Drug interactions via CYP enzyme inhibition or induction are not clinically significant for glycopyrrolate. [23,24]

Elimination

Renal Elimination: Glycopyrrolate is eliminated primarily by renal excretion, with approximately 80% of an IV dose recovered unchanged in urine within 24 hours. Elimination occurs via:

1. Glomerular filtration (majority)
2. Active tubular secretion (organic cation transporters)

The reliance on renal elimination means that glycopyrrolate clearance is reduced in renal impairment:

Despite the quaternary structure, glycopyrrolate is not efficiently removed by haemodialysis due to its protein binding and large molecular weight relative to dialysis membrane pore size. [25-27]

Duration of Action

The duration of glycopyrrolate effects varies by target organ:

The antisialagogue effect persists longer than the vagolytic effect, reflecting differences in receptor turnover and tissue sensitivity at different sites. This prolonged antisialagogue duration is clinically advantageous when premedication is given for secretion control. [28,29]

Pharmacodynamics: Systemic Effects

Cardiovascular Effects

Heart Rate: Glycopyrrolate produces dose-dependent increases in heart rate through M2 receptor blockade in the sinoatrial node. The vagolytic effect removes parasympathetic (vagal) restraint on the intrinsic pacemaker rate.

Comparison with Atropine: Glycopyrrolate produces less maximal tachycardia than atropine at equipotent antisialagogue doses. This reflects:

• Slower onset of action (better matching with neostigmine during reversal)
• Potentially lower M2 receptor efficacy
• Lack of CNS-mediated sympathetic activation

The onset of glycopyrrolate's vagolytic effect (2-3 minutes) more closely matches the onset of neostigmine-induced bradycardia than atropine (onset 1 minute), providing superior haemodynamic stability during neuromuscular reversal.

Atrioventricular Conduction: Glycopyrrolate increases AV nodal conduction velocity by blocking M2 receptors, which shortens the PR interval. This can be beneficial in reversal of drug-induced heart block but may facilitate rapid ventricular response in atrial fibrillation.

Blood Pressure: Glycopyrrolate has minimal direct effect on blood pressure. Unlike atropine, it does not cause transient hypotension (no CNS effect on vasomotor centre). The reflex tachycardia may slightly increase cardiac output in normovolaemic patients. [30-32]

Effects on Secretions

Antisialagogue Effect: Glycopyrrolate is a potent antisialagogue, approximately 5-10 times more potent than atropine for reducing salivary secretions. M3 receptor blockade on salivary gland acinar cells inhibits parasympathetic-stimulated saliva production.

Clinical Applications of Antisialagogue Effect:

1. Fibreoptic intubation: Reduced secretions improve visualisation and local anaesthetic efficacy
2. Ketamine anaesthesia: Counteracts ketamine-induced hypersalivation
3. Awake craniotomy: Reduces pooling of secretions
4. Oral/ENT surgery: Improved surgical field
5. Palliative care: Management of death rattle and sialorrhoea

Gastric Effects: Glycopyrrolate reduces gastric acid secretion and gastric volume, though not to the degree required for reliable aspiration prophylaxis. It is not a substitute for proton pump inhibitors or H2 receptor antagonists for patients at high aspiration risk. [33-35]

Respiratory Effects

Bronchodilation: Glycopyrrolate produces bronchodilation through M3 receptor blockade on bronchial smooth muscle. This effect is modest in healthy airways but can be clinically significant in:

• Patients with COPD
• Asthmatic patients
• Reactive airway disease

Inhaled glycopyrronium (Seebri Breezhaler) is approved for maintenance treatment of COPD.

Secretions: Reduced tracheobronchial secretions may benefit patients with excessive secretions but could theoretically increase mucus viscosity and impair mucociliary clearance. [36,37]

Ocular Effects

Glycopyrrolate produces minimal mydriasis and cycloplegia at standard anaesthetic doses due to poor penetration into the eye from the quaternary structure. [38]

Gastrointestinal Effects

Motility: M3 receptor blockade reduces GI smooth muscle tone and propulsive activity, potentially causing delayed gastric emptying and reduced intestinal peristalsis.

Clinical Pharmacology

Indication 1: Co-administration with Neostigmine

The most common anaesthetic use of glycopyrrolate is co-administration with neostigmine for reversal of non-depolarising neuromuscular blockade.

Rationale: Neostigmine is an acetylcholinesterase inhibitor that increases acetylcholine concentrations at both nicotinic (neuromuscular junction) and muscarinic (cardiac, glandular) receptors:

Glycopyrrolate blocks the undesired muscarinic effects while allowing the desired nicotinic effects at the neuromuscular junction.

Standard Dosing:

• Glycopyrrolate: 0.2 mg per 1 mg neostigmine (ratio 1:5)
• Typical adult dose: Glycopyrrolate 0.4-0.6 mg + Neostigmine 2-2.5 mg IV
• Maximum neostigmine dose: 5 mg (with glycopyrrolate 1 mg)

Timing:

• Administer together as a single mixture (can be drawn up in same syringe)
• Onset of glycopyrrolate (2-3 min) matches onset of neostigmine muscarinic effects
• Better haemodynamic stability than atropine-neostigmine combination

Haemodynamic Comparison: Glycopyrrolate vs Atropine with Neostigmine

The glycopyrrolate-neostigmine combination is preferred for routine reversal due to superior haemodynamic stability. Atropine may be preferred if the patient is already bradycardic prior to reversal. [41-45]

Indication 2: Antisialagogue Premedication

Fibreoptic Intubation:

• Dose: 0.2-0.4 mg IV or 0.4 mg IM, 30-60 minutes before procedure
• Reduces secretions that obscure fibreoptic view
• Improves efficacy of topical local anaesthesia (not diluted by secretions)

Ketamine Anaesthesia:

• Ketamine stimulates salivary secretions
• Glycopyrrolate 0.2 mg IV prevents hypersalivation
• Particularly important with ketamine in paediatric sedation

Oral/ENT Surgery:

• Premedication reduces secretions in surgical field
• Dose: 0.2-0.4 mg IM with other premedicants

Indication 3: Treatment of Bradycardia

Glycopyrrolate can treat intraoperative bradycardia of various causes:

Comparison with Atropine for Bradycardia:

For severe symptomatic bradycardia (hypotension, altered consciousness) or cardiac arrest, atropine's faster onset makes it preferred. For less urgent bradycardia, glycopyrrolate provides smoother heart rate elevation with fewer CNS effects. [46,47]

Indication 4: Reduction of Airway Secretions

Indications:

• Difficult airway management
• Awake intubation
• Expected prolonged intubation attempts
• Patients with copious secretions

Dose: 0.2-0.4 mg IV, 15-30 minutes before airway intervention

Dosing Summary

Contraindications

Drug Interactions

Adverse Effects and Complications

Common Adverse Effects

Serious Adverse Effects

Cardiovascular:

• Severe tachycardia (rare at standard doses)
• Arrhythmias (atrial or ventricular)
• Myocardial ischaemia (in susceptible patients with CAD)

Angle-Closure Glaucoma:

• Can precipitate acute angle-closure in predisposed eyes
• Screen for narrow angles preoperatively
• Rare with standard anaesthetic doses

Hyperthermia:

• Impaired sweating may contribute to heat accumulation
• Risk increased in paediatric patients and hot environments

Allergic Reactions:

• Rare hypersensitivity reactions reported
• Cross-reactivity with other anticholinergics possible

Anticholinergic Toxicity

At excessive doses or in overdose, anticholinergic toxicity produces a characteristic syndrome:

Peripheral Signs:

• Dry skin ("dry as a bone")
• Hyperthermia ("hot as a hare")
• Flushed skin ("red as a beet")
• Mydriasis ("blind as a bat")
• Tachycardia
• Urinary retention
• Ileus

Central Signs (NOT seen with glycopyrrolate due to quaternary structure):

• Agitation, confusion ("mad as a hatter")
• Hallucinations
• Seizures
• Coma

Management of Glycopyrrolate Toxicity:

• Supportive care (IV fluids, cooling, catheterisation)
• Beta-blockers for severe tachycardia
• Physostigmine is NOT indicated (glycopyrrolate does not cause central toxicity)
• Neostigmine may partially reverse peripheral effects

Comparison: Glycopyrrolate vs Atropine

Pharmacological Comparison

Clinical Comparison

When to Choose Each Drug

Choose Glycopyrrolate:

• Routine reversal of neuromuscular blockade
• Antisialagogue premedication
• Obstetric anaesthesia
• Elderly patients (avoid CNS effects)
• Non-urgent bradycardia

Choose Atropine:

• Cardiac arrest (per ARC guidelines)
• Severe symptomatic bradycardia requiring rapid response
• Organophosphate poisoning
• When CNS anticholinergic effect is desired (rare)

Australian/NZ Specific Considerations

TGA-Approved Formulations

Glycopyrrolate is TGA-approved in Australia in the following formulations:

The injection is stable at room temperature (up to 25°C), does not require refrigeration, and is compatible with 0.9% saline and 5% dextrose.

PBS Listing

Glycopyrrolate injection is NOT listed on the Pharmaceutical Benefits Scheme (PBS) for routine anaesthetic use. It is available as a hospital formulary drug funded through hospital drug budgets. Cost per 0.2 mg ampoule is approximately AUD $2-5 (generic).

Oral glycopyrrolate (Cuvposa) is PBS-listed with Authority Required for:

• Chronic severe drooling caused by neurological disorders in paediatric patients

ANZCA Guidelines

ANZCA PS09 (Guidelines on Sedation and/or Analgesia for Diagnostic and Interventional Medical, Dental or Surgical Procedures) acknowledges antisialagogue premedication as appropriate for selected procedures. The Australian and New Zealand College of Anaesthetists endorses evidence-based use of glycopyrrolate-neostigmine combination for neuromuscular reversal in accordance with manufacturer recommendations and established anaesthetic practice.

Availability

Glycopyrrolate injection is widely available in Australian hospitals and day surgery facilities. Rural and remote facilities typically stock glycopyrrolate as part of standard anaesthetic drug kits.

Indigenous Health Considerations

Limited pharmacokinetic data exist specifically for Aboriginal and Torres Strait Islander populations regarding glycopyrrolate. However, several clinical and cultural factors warrant consideration in perioperative care. Higher rates of chronic kidney disease in some Indigenous communities may affect glycopyrrolate elimination given its primary renal clearance; in patients with known renal impairment (eGFR <30 mL/min/1.73m2), consider dose reduction. Cardiovascular disease prevalence, including ischaemic heart disease, is elevated in Indigenous populations, warranting caution with drugs that increase heart rate and myocardial oxygen demand. Anticholinergic medications may exacerbate urinary retention in patients with prostatic disease, which should be considered in older Aboriginal men.

Remote and rural communities with high Indigenous populations may have limited access to specialist anaesthesia services. Glycopyrrolate is generally available in remote health facilities as part of emergency drug kits. Patient education about anticipated effects (dry mouth, potential urinary retention) should be delivered through culturally appropriate communication, involving Aboriginal Health Workers or interpreters where beneficial. Family involvement in perioperative care decisions should be supported, consistent with concepts of kinship and collective decision-making.

Māori health considerations in New Zealand similarly emphasise culturally safe care with whānau (family) involvement. Ensuring tikanga (cultural protocols) are respected during perioperative care enhances trust and engagement with health services. Higher rates of cardiovascular and renal disease in Māori populations support careful assessment before anticholinergic use.

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs frequently test the following glycopyrrolate and anticholinergic concepts:

1. Structure-activity relationship: Quaternary ammonium vs tertiary amine, inability to cross BBB
2. Mechanism: Competitive muscarinic antagonism at M1, M2, M3 receptors
3. Receptor types: M2 (heart), M3 (glands, smooth muscle)
4. Pharmacokinetics: Poor oral bioavailability, renal elimination, short half-life
5. Comparison with atropine: Onset, duration, CNS effects, antisialagogue potency
6. Neostigmine combination: Rationale, dosing ratio (1:5), timing advantage
7. Contraindications: Angle-closure glaucoma, myasthenia gravis
8. Obstetric use: Preferred over atropine (no placental transfer)

Primary Viva Question Themes

Viva scenarios typically explore:

• Mechanism of action at muscarinic receptors in detail
• Rationale for glycopyrrolate-neostigmine combination
• Comparison between glycopyrrolate and atropine
• Management of anticholinergic toxicity
• Selection of anticholinergic for specific clinical scenarios
• Structure-activity relationships in anticholinergic drugs

High-Yield Comparisons

Glycopyrrolate vs Atropine Summary (frequently examined):

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 68-year-old man (75 kg) is undergoing laparoscopic cholecystectomy under general anaesthesia with rocuronium neuromuscular blockade. At the end of surgery, you plan to reverse the neuromuscular blockade using neostigmine and glycopyrrolate. The patient has a history of well-controlled hypertension but no other comorbidities.

(a) Describe the mechanism of action of glycopyrrolate at the molecular and cellular level. Explain why it is co-administered with neostigmine. (6 marks)

(b) Compare the pharmacokinetic properties of glycopyrrolate and atropine, explaining how the structural differences affect their clinical profiles. (6 marks)

(c) The patient develops intraoperative bradycardia (heart rate 38 bpm) with hypotension during peritoneal insufflation before you are ready to reverse. Outline your management, including your choice of anticholinergic and the rationale. (4 marks)

(d) Outline the contraindications to glycopyrrolate and situations where atropine would be preferred. (4 marks)

---

Model Answer:

(a) Mechanism of Action and Rationale for Co-administration with Neostigmine (6 marks)

Molecular Mechanism (3 marks):

• Glycopyrrolate is a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3)
• Muscarinic receptors are G-protein coupled receptors (metabotropic)
• M2 receptors (heart): Coupled to Gi protein; activation inhibits adenylyl cyclase and opens GIRK K+ channels, slowing heart rate. Glycopyrrolate blockade prevents bradycardia.
• M3 receptors (glands): Coupled to Gq protein; activation stimulates phospholipase C, increasing intracellular calcium and secretion. Glycopyrrolate blockade reduces secretions.
• Binding is competitive and reversible, following law of mass action

Rationale for Co-administration (3 marks):

• Neostigmine is an acetylcholinesterase inhibitor that increases acetylcholine at all cholinergic synapses
• At the neuromuscular junction (nicotinic receptors): Desired effect - reverses non-depolarising NMB
• At muscarinic receptors: Undesired effects - bradycardia (M2), hypersalivation, bronchospasm (M3)
• Glycopyrrolate selectively blocks muscarinic effects without affecting nicotinic receptor-mediated reversal
• Onset of glycopyrrolate (2-3 min) matches onset of neostigmine muscarinic effects, providing haemodynamic stability

(b) Pharmacokinetic Comparison (6 marks)

Structure-Effect Relationship (2 marks): The quaternary nitrogen in glycopyrrolate carries a permanent positive charge, preventing passive diffusion across lipid membranes (BBB, placenta). Atropine's tertiary nitrogen is only 50% ionised at physiological pH, allowing un-ionised fraction to cross lipid barriers.

(c) Management of Intraoperative Bradycardia (4 marks)

Immediate Management (2 marks):

1. Stop surgical stimulus (deflate peritoneum temporarily)
2. Check depth of anaesthesia (light anaesthesia increases vagal tone)
3. Ensure adequate oxygenation and ventilation
4. Administer anticholinergic

Drug Selection (2 marks):

• Atropine 0.6-1.2 mg IV is preferred for this scenario because:

  • Faster onset (1 minute vs 2-3 minutes for glycopyrrolate)
  • Patient is symptomatic (hypotension) requiring rapid response
  • Greater magnitude of heart rate increase

• Glycopyrrolate 0.4 mg IV is an alternative if atropine unavailable or if more gradual response acceptable

• If bradycardia persists or recurs, may need repeat dosing or address underlying cause

• Consider vasopressor (ephedrine, phenylephrine) for persistent hypotension

(d) Contraindications and Situations Favouring Atropine (4 marks)

Contraindications to Glycopyrrolate (2 marks):

• Angle-closure glaucoma (untreated) - risk of acute attack
• Myasthenia gravis (when used alone without cholinesterase inhibitor)
• Paralytic ileus
• Tachyarrhythmias (relative)
• Prostatic hypertrophy with urinary retention (relative)
• Severe coronary artery disease (relative - tachycardia increases O2 demand)

Situations Where Atropine is Preferred (2 marks):

• Cardiac arrest (ARC guidelines - atropine 1 mg IV)
• Severe symptomatic bradycardia requiring rapid response
• Organophosphate/carbamate poisoning (high doses required)
• Pre-existing bradycardia before neostigmine reversal
• When CNS anticholinergic effect is specifically desired (rare)
• Resource-limited settings where only atropine available

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: You are anaesthetising a 32-year-old woman for an urgent caesarean section under general anaesthesia. She weighs 85 kg and is at term gestation. After intubation and surgical delivery of the baby, rocuronium neuromuscular blockade needs to be reversed. Tell me about your approach to reversal.

Candidate:

Reversal Options (3 marks):

"I have two main options for reversal of rocuronium in this patient:

1. Sugammadex: Rapid, reliable reversal independent of block depth. Preferred for deep block or when rapid reversal required.

2. Neostigmine with anticholinergic: Traditional reversal, effective once spontaneous recovery has commenced (TOF count ≥2, preferably ≥4). More economical.

Given this is a post-caesarean patient who is now delivered, I would likely use neostigmine with glycopyrrolate, assuming adequate spontaneous recovery has occurred. I would monitor with peripheral nerve stimulator."

Examiner: Why would you choose glycopyrrolate over atropine in this obstetric patient?

Candidate:

Rationale for Glycopyrrolate (3 marks):

"Glycopyrrolate is preferred in obstetric patients for several reasons:

1. No placental transfer: Glycopyrrolate is a quaternary ammonium compound that does not cross the placenta. Although the baby has been delivered, if I needed to give anticholinergic before delivery, glycopyrrolate would not cause fetal tachycardia.

2. No CNS effects: Glycopyrrolate does not cross the blood-brain barrier, so it won't cause sedation or confusion. This is particularly important postpartum when we want the mother alert for bonding with her baby and for breastfeeding decisions.

3. Better onset matching with neostigmine: The onset of glycopyrrolate (2-3 minutes) matches the onset of neostigmine's muscarinic effects better than atropine (1 minute), providing more stable haemodynamics during reversal.

4. Longer antisialagogue effect: If she had required airway management with secretions, glycopyrrolate provides 4-8 hours of antisialagogue effect compared to 1-2 hours with atropine."

Examiner: What is the standard dosing regimen for glycopyrrolate-neostigmine?

Candidate:

Dosing (2 marks):

"The standard ratio is glycopyrrolate 0.2 mg per 1 mg of neostigmine, which is a 1:5 ratio.

For this patient, a typical adult reversal dose would be:

• Neostigmine 2.5 mg (maximum 5 mg)
• Glycopyrrolate 0.5 mg

These can be drawn up in the same syringe and administered together as a single IV injection. I would administer this once the TOF count is at least 2, preferably 4 or more, to ensure adequate spontaneous recovery is underway for effective reversal."

Examiner: The patient asks why she might have a dry mouth after the anaesthetic. How would you explain this?

Candidate:

Patient Explanation (2 marks):

"I would explain in lay terms:

'The medication we gave to protect your heart during the reversal of the muscle relaxant also reduces the amount of saliva your mouth makes. This is a normal, expected effect and will wear off over the next few hours. The dry mouth feeling is temporary and not harmful. You can sip water to keep your mouth comfortable.

This medication was specifically chosen because it doesn't make you drowsy or affect your thinking, which is important so you can be alert with your baby.'"

Examiner: If this patient had known angle-closure glaucoma, how would you modify your approach?

Candidate:

Modified Approach (3 marks):

"Angle-closure glaucoma is a contraindication to anticholinergic drugs because they can precipitate an acute attack by causing mydriasis and blocking aqueous humour outflow.

My modified approach would be:

1. Confirm glaucoma status: Determine if the patient has been treated (laser iridotomy or surgical iridectomy). If she has had definitive treatment, the angle is open and anticholinergics are safe.

2. If untreated angle-closure: I would use sugammadex for reversal instead of neostigmine. Sugammadex does not require anticholinergic co-administration and provides rapid, reliable reversal.

3. Dosing: Sugammadex 2-4 mg/kg depending on depth of block. At TOF count ≥2: 2 mg/kg; for deep block (PTC 1-2): 4 mg/kg.

4. Liaise with ophthalmology if there's any concern about precipitating acute glaucoma.

This scenario highlights one of the advantages of sugammadex - it avoids the muscarinic side effects of neostigmine reversal entirely, including the need for anticholinergic co-administration."

Examiner: Good. What monitoring would you use to assess adequacy of reversal?

Candidate:

Monitoring (2 marks):

"I would use quantitative neuromuscular monitoring - preferably acceleromyography at the adductor pollicis muscle. Neostigmine should only be given when TOF count ≥2 (preferably ≥4). Target TOF ratio ≥0.9 before extubation to ensure adequate pharyngeal muscle function and respiratory strength."

Examiner: Thank you. Good understanding demonstrated.

Total: 15 marks (3 + 3 + 2 + 2 + 3 + 2)

---

References

1. Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983;38(12):1195-1204. PMID: 6660459

2. Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633-642. PMID: 8249551

3. Proakis AG, Harris GB. Comparative penetration of glycopyrrolate and atropine across the blood-brain and placental barriers in anesthetized dogs. Anesthesiology. 1978;48(5):339-344. PMID: 646152

4. Abboud TK, Read J, Miller F, Chen T, Valle R, Henriksen EH. Use of glycopyrrolate in the parturient: effect on the maternal and fetal heart and uterine activity. Obstet Gynecol. 1981;57(2):224-227. PMID: 7465129

5. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279-290. PMID: 9647869

6. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219-233. PMID: 16879488

7. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Brunton LL, ed. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill; 2011:219-238.

8. Kanto J, Klotz U. Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate. Acta Anaesthesiol Scand. 1988;32(2):69-78. PMID: 3281504

9. Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther. 1980;28(1):78-81. PMID: 7389250

10. Salem MG, Richardson JC, Meadows GA, Lamplugh G, Lai KM. Comparison between glycopyrrolate and atropine in a mixture with neostigmine for reversal of neuromuscular blockade. Studies in patients following open heart surgery. Br J Anaesth. 1985;57(2):184-187. PMID: 3970797

11. Mirakhur RK, Dundee JW, Jones CJ. Evaluation of the anticholinergic actions of glycopyrronium bromide. Br J Clin Pharmacol. 1978;5(1):77-84. PMID: 623702

12. Mirakhur RK, Dundee JW, Clarke RS. Glycopyrrolate-neostigmine mixture for antagonism of neuromuscular block: comparison with atropine-neostigmine mixture. Br J Anaesth. 1977;49(8):825-829. PMID: 901867

13. Ostheimer GW. A comparison of glycopyrrolate and atropine during reversal of nondepolarizing neuromuscular block with neostigmine. Anesth Analg. 1977;56(2):182-186. PMID: 557915

14. Baraka A, Yared JP, Karam AM, Winnie A. Glycopyrrolate-neostigmine and atropine-neostigmine mixtures affect postanesthetic arousal times differently. Anesth Analg. 1980;59(6):431-434. PMID: 7189983

15. Ramamurthy S, Shaker MH, Winnie AP. Glycopyrrolate as a substitute for atropine in neostigmine reversal of muscle relaxant drugs. Can Anaesth Soc J. 1972;19(4):399-411. PMID: 5044188

16. Mirakhur RK. Anticholinergic drugs and anaesthesia. Can J Anaesth. 1987;34(5):517-522. PMID: 3311433

17. Mirakhur RK, Dundee JW, Connolly JD. Studies of drugs given before anaesthesia. XVII: anticholinergic premedicants. Br J Anaesth. 1979;51(4):339-345. PMID: 377037

18. Stoelting RK. Pharmacology and Physiology in Anesthetic Practice. 4th ed. Lippincott Williams & Wilkins; 2006:261-275.

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols.